Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer
Celcuity (NASDAQ:CELC), a clinical-stage biotechnology company focused on targeted oncology therapies, has scheduled a conference call and webcast for July 28, 2025, at 8:00 AM ET to present topline results from the PIK3CA Wild-Type Cohort of their Phase 3 VIKTORIA-1 trial in HR+/HER2- advanced breast cancer.
The management team will host the presentation with a live webcast available, and participants can register for the teleconference in advance. A replay will be accessible on Celcuity's website after the event.
Celcuity (NASDAQ:CELC), un'azienda biotecnologica in fase clinica specializzata in terapie oncologiche mirate, ha programmato una conference call e una diretta web per il 28 luglio 2025 alle 8:00 AM ET per presentare i risultati principali della coorte PIK3CA Wild-Type del loro trial di Fase 3 VIKTORIA-1 nel carcinoma mammario avanzato HR+/HER2-.
Il team dirigenziale condurr脿 la presentazione con una diretta web disponibile, e i partecipanti possono registrarsi in anticipo per la teleconferenza. Una registrazione sar脿 accessibile sul sito di Celcuity dopo l'evento.
Celcuity (NASDAQ:CELC), una empresa biotecnol贸gica en fase cl铆nica centrada en terapias oncol贸gicas dirigidas, ha programado una llamada de conferencia y una transmisi贸n en vivo para el 28 de julio de 2025 a las 8:00 AM ET para presentar los resultados principales de la cohorte PIK3CA Wild-Type de su ensayo de Fase 3 VIKTORIA-1 en c谩ncer de mama avanzado HR+/HER2-.
El equipo directivo realizar谩 la presentaci贸n con una transmisi贸n en vivo disponible, y los participantes pueden registrarse previamente para la teleconferencia. Una repetici贸n estar谩 disponible en el sitio web de Celcuity despu茅s del evento.
Celcuity (NASDAQ:CELC)電� 響滌爜 頃晹 旃橂鞝滌棎 欷戩爯鞚� 霊� 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓搿�, 2025雲� 7鞗� 28鞚� 鞓れ爠 8鞁�(霃欕秬 鞁滉皠)鞐� HR+/HER2- 歆勴枆靹� 鞙犽癌鞎� 雽�靸� 3靸� VIKTORIA-1 鞁滍棙鞚� PIK3CA 鞎检儩順� 旖旐樃韸� 欤检殧 瓴瓣臣毳� 氚滍憸頃橁赴 鞙勴暣 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼毳� 鞓堨爼頄堨姷雼堧嫟.
瓴届榿歆勳澊 氚滍憸毳� 欤检禍頃橂┌ 鞁れ嫓臧� 鞗轨簮鞀ろ姼臧� 鞝滉车霅橂┌, 彀戈皜鞛愲姅 靷爠鞐� 鞝勴檾 須岇潣 霌彪鞚� 臧�電ロ暕雼堧嫟. 鞚措菠韸� 頉� Celcuity 鞗轨偓鞚错姼鞐愳劀 雼れ嫓氤搓赴毳� 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
Celcuity (NASDAQ:CELC), une soci茅t茅 biotechnologique en phase clinique sp茅cialis茅e dans les th茅rapies oncologiques cibl茅es, a programm茅 une conf茅rence t茅l茅phonique et une webdiffusion pour le 28 juillet 2025 脿 8h00 ET afin de pr茅senter les r茅sultats principaux de la cohorte PIK3CA Wild-Type de leur essai de phase 3 VIKTORIA-1 dans le cancer du sein avanc茅 HR+/HER2-.
L'茅quipe de direction animera la pr茅sentation avec une webdiffusion en direct disponible, et les participants peuvent s'inscrire 脿 la t茅l茅conf茅rence 脿 l'avance. Une rediffusion sera accessible sur le site web de Celcuity apr猫s l'茅v茅nement.
Celcuity (NASDAQ:CELC), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf zielgerichtete Onkologie-Therapien, hat eine Telefonkonferenz und Webcast f眉r den 28. Juli 2025 um 8:00 Uhr ET angesetzt, um die wichtigsten Ergebnisse der PIK3CA Wild-Type Kohorte ihrer Phase-3-Studie VIKTORIA-1 bei fortgeschrittenem HR+/HER2- Brustkrebs vorzustellen.
Das Management-Team wird die Pr盲sentation leiten, die als Live-Webcast verf眉gbar sein wird, und Teilnehmer k枚nnen sich im Voraus f眉r die Telefonkonferenz registrieren. Eine Aufzeichnung wird nach der Veranstaltung auf der Celcuity-Website abrufbar sein.
- None.
- None.
MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial.
Webcast and Conference Call Information
The Celcuity management team will host a webcast/conference call on Monday, July 28, 2025 at 8:00 a.m. ET to discuss the topline results from the Phase 3 VIKTORIA-1 trial. Those who would like to participate may access the live webcast , or register in advance for the teleconference . A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K伪, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. 听A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about Celcuity鈥檚 active clinical trials can be found at听. Celcuity is headquartered in Minneapolis.听Further information about Celcuity can be found at听. Follow us on听听补苍诲听.
Contacts:听
Celcuity Inc.听
Brian Sullivan, 听
Vicky Hahne, 听
(763) 392-0123听
ICR Healthcare
Patti Bank, 听
(415) 513-1284
FAQ
When will Celcuity (CELC) announce the VIKTORIA-1 Phase 3 trial results?
What is the VIKTORIA-1 trial studying for Celcuity (CELC)?
How can investors access Celcuity's VIKTORIA-1 trial results presentation?
What type of breast cancer is being targeted in Celcuity's VIKTORIA-1 trial?
